{"id":803,"date":"2022-05-30T10:38:53","date_gmt":"2022-05-30T10:38:53","guid":{"rendered":"http:\/\/events.marketsandmarkets.com\/blog\/?p=803"},"modified":"2022-05-30T10:38:53","modified_gmt":"2022-05-30T10:38:53","slug":"speaker-spotlight-namit-kumar-3rd-annual-marketsandmarkets-single-cell-analysis-conference","status":"publish","type":"post","link":"https:\/\/events.marketsandmarkets.com\/blognew\/speaker-spotlight-namit-kumar-3rd-annual-marketsandmarkets-single-cell-analysis-conference\/","title":{"rendered":"Speaker Spotlight &#8211; &#8216;NAMIT KUMAR&#8217; : 3rd Annual MarketsandMarkets Single Cell Analysis Conference!"},"content":{"rendered":"\n<p>Just over 3 weeks remain until the <em><strong>3<\/strong><sup><strong>rd <\/strong><\/sup><strong>Annual MarketsandMarkets Single Cell Analysis Conference<\/strong><\/em> kicks off at the <em>Hyatt Regency Boston\/Cambridge<\/em> on the <em><strong>23<\/strong><sup><strong>rd<\/strong><\/sup><strong> &amp; 24<\/strong><sup><strong>th<\/strong><\/sup><strong> of June 2022<\/strong><\/em>. With <strong>100+<\/strong> attendees &amp; stellar presentations from over <strong>15+ industry experts and leaders<\/strong>, we\u2019re counting down the days till we can finally host you in person!<br> <br>We\u2019re hugely excited as the keynote speakers shall be sharing their findings, ideas &amp; foresight into the future of cell analysis &amp; how emerging technologies can propel forward, the growth of the healthcare ecosystem.<br> \u00a0<br>As we sat down with <strong>Namit Kumar<\/strong>, <em>Principal Scientist<\/em> in the Informatics &amp; Predictive Sciences Division at <em>Bristol Myers Squibb<\/em>, he was kind enough to give us a tiny glimpse into his presentation.<br> <br><br><br>1. What are the recent advances in single-cell analysis and current challenges that need our immediate attention?<\/p>\n\n\n\n<p><u>Notable Recent Advances<\/u>:<\/p>\n\n\n\n<ul><li>Spatial\ntranscriptomics \u2013 Including applications like profiling spatial detail on T cell\ninflux in the tumor microenvironment.<\/li><li>Single\ncell Multi-omics readout such as:<ul><li>RNA\n+ protein (CITE-seq, REAP-seq), <\/li><\/ul><ul><li>RNA + ATAC<\/li><\/ul><ul><li>scRNA + scTCR seq<br>\n<br>\n<\/li><\/ul><\/li><\/ul>\n\n\n\n<p><u>Current Challenges<\/u>:<\/p>\n\n\n\n<ul><li>It has proven challenging to\nestablish smooth workflows to profile patient samples from clinical studies,\nespecially for solid tumor and diseased tissue.<\/li><li>There is a need to ensure\ninformation derived single-cell sequencing platforms can be extrapolated to\nwork with more traditional and commonly used platforms like bulk RNA-seq &amp;\nIHC.<\/li><\/ul>\n\n\n\n<p><br>\n2. What are noteworthy points from your presentation which shall\nhelp build &amp; expand the knowledge base of the attendees?&nbsp; <\/p>\n\n\n\n<ul><li>Immune\ncheckpoint blockade therapies have drastically improved patient survival in\nnumerous cancer types, yet only a subset of patients respond favourably.<\/li><li>Current\nstudy uses a multi-omics (integrated scRNA and scTCR sequencing) approach to\nidentify distinct cellular states of CD8+ T cells and develop predictive\nsignatures.<\/li><li>Intended\nimpact of this study is to develop predictive gene signatures from pre-clinical\nmodels which could help improve patient selection in clinical trials and\nultimately enhance patient benefit.<\/li><\/ul>\n\n\n\n<p>_________________________________________________________________________________________________________________________________<br><br>Namit Kumar received his PhD from Rutgers University, New jersey with a dual major in Computational Biology and Molecular Biosciences conducting research on identifying drivers of intestinal development and disease. Prior to his BMS, Dr. Kumar worked at Merck developing new single-cell sequencing methodologies like REAP-seq with applications including identifying and validating drug targets. His current research at BMS broadly focusses on using multi-omics approaches to identify clinically applicable biomarkers and indication selection strategies for drugs moving in early clinical trials.<br><\/p>\n\n\n\n<p>Watch this space for more excerpts from key industry leaders sharing their outlook on the latest innovations, challenges &amp; the path forward!<br> <br><a href=\"https:\/\/events.marketsandmarkets.com\/3rd-annual-marketsandmarkets-single-cell-analysis-conference\/\">CLICK HERE TO EXPLORE &amp; REGISTER FOR THE EVENT<\/a> or reach out to us at <a href=\"mailto:events@marketsandmarkets.com\">events@marketsandmarkets.com<\/a> regarding any queries you may have. We\u2019d be happy to assist you!<\/p>\n\n\n\n<p>Ayush Kanitkar<br>MarketsandMarkets<br>+91-8975985061<br> <br> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Just over 3 weeks remain until the 3rd Annual MarketsandMarkets Single Cell Analysis Conference kicks off at the Hyatt Regency Boston\/Cambridge on the 23rd &amp; 24th of June 2022. With 100+ attendees &amp; stellar presentations from over 15+ industry experts and leaders, we\u2019re counting down the days till we can finally host you in person! [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[3,4],"tags":[57,285,254,255],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/803"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=803"}],"version-history":[{"count":17,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/803\/revisions"}],"predecessor-version":[{"id":822,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/803\/revisions\/822"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/817"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}